BRAF and colorectal carcinoma: From 2018 to 2020, 218 CRC patients were randomized 1:2, in the phase II ATEZOTRIBE trial, to receive first-line FOLFOXIRI plus bevacizumab with or without atezolizumab, followed by maintenance treatment (fluorouracil and leucovorin plus bevacizumab with or without atezolizumab), irrespective of RAS and BRAF mutational status [90].